Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of CINtec®PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas ® 4800 HPV Test. This biomarker technology simplifies clinical decision making by providing easy to understand results so that clinicians and women are clear on next steps. The CINtecPLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It enables c...
Source: Roche Media News - March 11, 2020 Category: Pharmaceuticals Source Type: news

Cancer-causing HPV can hit you even if you had the vaccination
Jessica Donald, from Birmingham, thought she'd get the all-clear after a cervical cancer screening test at her GP - only to be told she'd tested positive for human papillomavirus. (Pictured, stock image.) (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2020 Category: Consumer Health News Source Type: news

The incidence of oropharyngeal cancer and rate of human papillomavirus vaccination coverage in Florida, 2011 through 2015.
CONCLUSIONS:The authors found relatively higher and increasing incidence rate of OPC in Florida and lower rate of HPV vaccination among adolescents in Florida than in the nation overall.PRACTICAL IMPLICATIONS:The trends illustrated may stimulate policy changes to increase HPV vaccination for children and enhance the understanding of its benefits. (Source: Dental Technology Blog)
Source: Dental Technology Blog - January 22, 2020 Category: Dentistry Source Type: news

Cervical cancer could be on its way to extinction thanks to improved testing and vaccination
A new detection method rolled out last month looks for traces of the human papillomavirus (HPV), which cause nearly all cervical tumours. (Source: the Mail online | Health)
Source: the Mail online | Health - January 20, 2020 Category: Consumer Health News Source Type: news

Routine HPV Testing May Be Warranted for Sinonasal Cancers
FRIDAY, Jan. 3, 2020 -- Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online Dec. 30 in Cancer. Jamie R. Oliver, from the New York University School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2020 Category: Pharmaceuticals Source Type: news

Improved Saliva Test Aids Detection of HPV-16 Improved Saliva Test Aids Detection of HPV-16
Use of acoustofluidic separation technology (AFS) doubles detection of oropharyngeal cancer-associated human papillomavirus-16 (HPV-OPC) in saliva, according to an international group of investigatorsReuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 27, 2019 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening
Human papillomavirus (HPV) genotyping for HPV-16 and HPV-18, followed by reflex cytological testing in women with positive results, is more likely than cytological testing alone to detect cervical intraepithelial neoplasia (CIN) grade 2 or higher, according to results from the FRIDA study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Roche Packs New FDA-Approved Test in Its Arsenal
Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800/8800 system. Cobas Babesia detects parasites that live in red blood cells. Roche said this test is an important advancement because the Babesia parasite cannot be detected in traditional plasma or serum samples. The test can detect the four-common species of Babesia and employs the new whole blood collection tube, which simplifies Babesia sample preparation by consolidating steps within the tube itself to provide an efficient solutio...
Source: MDDI - September 20, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news

Confused About Who Should Get the HPV Vaccine, and When? The CDC Has New Recommendations
For its first few years on the market, the human papillomavirus (HPV) vaccine was approved only for young girls. Over time, the U.S. Food and Drug Administration (FDA) has broadened its approval to include boys, as well as adults up to age 45—allowing more people to get the cancer-preventing vaccine, but also breeding confusion about who should get vaccinated and when. On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) released new recommendations, based on guidance from the Advisory Committee on Immunization Practices, that should clear up some of that confusion. The CDC reaffirmed that its prior...
Source: TIME: Health - August 15, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized onetime public health Source Type: news

Why Sexually Transmitted Infections Can ’t Shake Their Stigma
We live in an era of sex positivity — until we get positive test results. And that’s unfortunate, because S.T.I.s are on the rise. (Source: NYT Health)
Source: NYT Health - August 13, 2019 Category: Consumer Health News Authors: Jen Gunter Tags: your-feed-selfcare Sexually Transmitted Diseases Herpes Viruses Human Papillomavirus (HPV) your-feed-science your-feed-health Source Type: news

Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Roche has expanded the Global Access Program, originally established to increase availability of HIV diagnostics in underserved countries, to include diagnostic tests for tuberculosis, hepatitis, and human papillomavirus (HPV). Increased access to reliable diagnostics will allow early, possibly life-saving, detection and decrease the spread of these diseases. Roche launched the program in 2014 and began offering the added tests in July. The molecular diagnostics available include tests for determination of HIV-1 viral load, early diagnosis of HIV-1 and -2 in young infants, Mycobacterium tuberculosis (MTB) and rifampin/ison...
Source: MDDI - August 9, 2019 Category: Medical Devices Authors: Jenevieve Blair Polin Tags: IVD Source Type: news

Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
Roche announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. (Source: Roche Media News)
Source: Roche Media News - July 22, 2019 Category: Pharmaceuticals Source Type: news

Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
Roche announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. (Source: Roche Investor Update)
Source: Roche Investor Update - July 22, 2019 Category: Pharmaceuticals Source Type: news

Could Myriad ’s New Study Results Be Game Changers For Cancer Patients?
The 2019 American Society of Clinical Oncology’s meeting might be in the books, but the impact of some of the data released at the conference are certain to have implications for cancer patients for years to come. Myriad Genetics presented data from several studies at ASCO that will no doubt have a long-lasting impact on cancer detection and treatment. The Salt Lake City, UT-based company spoke with MD+DI during ASCO about results from both colorectal cancer and breast cancer studies. Some of the most talked-about results came from the Phase III POLO Study, which looked at how well the BRACAnalysis CDx id...
Source: MDDI - June 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Some Cervical Cancer Screening Strategies More Cost-Effective
TUESDAY, May 14, 2019 -- A cervical cancer screening strategy that involves cytologic testing every three years from ages 21 to 29 years and then continuing cytologic testing or switching to low-cost high-risk human papillomavirus (hrHPV) testing... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 14, 2019 Category: Pharmaceuticals Source Type: news